article thumbnail

Is your retail health growth strategy aligning with the evolving needs of your customers?

Frost & Sullivan

This shift is benefiting pharmaceutical companies and contract research organizations (CROs) by facilitating decentralized trials, simplifying patient recruitment and retention, and reducing the number of phase 3 clinical sites. Central contracts with retailers are providing convenient access to numerous trial locations.

Retail 52
article thumbnail

Is your retail health growth strategy aligning with the evolving needs of your customers?

Frost & Sullivan

This shift is benefiting pharmaceutical companies and contract research organizations (CROs) by facilitating decentralized trials, simplifying patient recruitment and retention, and reducing the number of phase 3 clinical sites. Central contracts with retailers are providing convenient access to numerous trial locations.

Retail 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 10 Strategic Imperatives Driving Innovation in AI-Enhanced Drug Discovery and Development

Frost & Sullivan

This is fueling the growing demand for outsourcing, with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) driving industry growth. Conversely, small-to-mid, and emerging biopharma players, with 1 or 2 molecules in the pipeline, contribute over 16%.

article thumbnail

Avance Clinical Earns Frost & Sullivan’s 2023 Best Practices Customer Value Leadership Award for Delivering High-quality Clinical Trials Based on Globally Accepted Data

Frost & Sullivan

San Antonio, TX — 7 th Aug, 2023 — Frost & Sullivan recently researched the Asia-Pacific biotechnology contract research organization industry and, based on its findings, recognizes Avance Clinical with the 2023 Customer Value Leadership Award. In addition, the attractive 43.5%

article thumbnail

Are You Leveraging the Drug Discovery and Early Development Outsourcing Services Ecosystem to Accelerate Growth?

Frost & Sullivan

Growing demand for outsourcing, with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) leading industry growth. Top 10 pharma companies contribute only 4-5% to R&D pipeline; top 25 contribute less than 10%.

article thumbnail

How does your company’s benchmarking performance stack up against the leading precision health companies in the ecosystem?

Frost & Sullivan

Utilize this distinctive competitive benchmarking tool to elevate your future growth potential significantly. The Frost Radar™ serves as a powerful analytical tool for conducting a comprehensive ‘Growth Audit’ across various industries, evaluating key companies on essential criteria related to innovation and growth.